Stonvex publishes market data and research only. Not investment advice. Not a registered investment advisor. Read disclaimer.

CADL

Live52w high -14.8%

Core line items from CADL's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

Entity: CANDEL THERAPEUTICS, INC.·Source: SEC EDGAR companyfacts

Metric	Annual 2022 2022-12-31	Annual 2021 2021-12-31	Annual 2020 2020-12-31
Revenue	$125.00K	$125.00K	$125.00K
Operating Income	$-34.72M	$-25.73M	$-13.81M
Net Income	$-18.79M	$-36.12M	$-17.68M
EPS (Diluted)	$-0.65	$-1.91	Not available
Total Assets	$77.69M	$89.20M	$38.28M
Total Liabilities	$29.98M	$25.07M	$12.78M
Cash & Equivalents	$70.06M	$82.64M	$35.05M
Free Cash Flow OCF − CapEx	$-32.72M	$-24.05M	$-10.55M
Shares Outstanding	28.92M	28.69M	11.64M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data.

Core line items from CADL's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

52w high -14.8%

Entity: CANDEL THERAPEUTICS, INC.·Source: SEC EDGAR companyfacts

Metric	Annual 2022 2022-12-31	Annual 2021 2021-12-31	Annual 2020 2020-12-31
Revenue	$125.00K	$125.00K	$125.00K
Operating Income	$-34.72M	$-25.73M	$-13.81M
Net Income	$-18.79M	$-36.12M	$-17.68M
EPS (Diluted)	$-0.65	$-1.91	Not available
Total Assets	$77.69M	$89.20M	$38.28M
Total Liabilities	$29.98M	$25.07M	$12.78M
Cash & Equivalents	$70.06M	$82.64M	$35.05M
Free Cash Flow OCF − CapEx	$-32.72M	$-24.05M	$-10.55M
Shares Outstanding	28.92M	28.69M	11.64M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data.